Pacific Biosciences of California (Pacific Biosciences of California) Net Issuance of Preferred Stock

: $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Pacific Biosciences of California's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. The number is 0, which means that Pacific Biosciences of California has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Pacific Biosciences of California's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Pacific Biosciences of California Net Issuance of Preferred Stock Historical Data

The historical data trend for Pacific Biosciences of California's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Pacific Biosciences of California Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Pacific Biosciences of California Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Pacific Biosciences of California Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

P09:Germany P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Executives

Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025